Safety and efficacy of adefovir therapy for lamivudine-resistant hepatitis B virus infection in renal transplant recipients

Journal of the Formosan Medical Association

Volumn 111, Issue 8, 2012, Pages 439-444

  Lai, Hsin Wu ^a,b   Chang, Chiu Chun ^a,b   Chen, Tan Hsia ^a,b   Tsai, Ming Chang ^a,b   Chen, Tzy Yen ^a   Lin, Chun Che ^a,b  

^a CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Adefovir dipivoxil; Hepatitis B surface antigen; Lamivudine resistance; Nephrotoxicity; Renal transplant recipient

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; LAMIVUDINE; LIVER ENZYME; VIRUS DNA;

ADULT; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HEPATITIS B; HUMAN; HUMAN TISSUE; KIDNEY FAILURE; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MALE; MONOTHERAPY; NEPHROTOXICITY; TREATMENT DURATION; TREATMENT OUTCOME;

ADENINE; ADULT; AGED; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; KIDNEY TRANSPLANTATION; LAMIVUDINE; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 84865613156     PISSN: None     EISSN: 09296646     Source Type: Journal    
DOI: 10.1016/j.jfma.2011.05.010     Document Type: Article

References (17)

1. Fabrizi F., Martin P., Dixit V., Kanwal F., Dulai G. HBsAg seropositive status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant 2005, 5:2913.
2. Mathurin P., Mouquet C., Poynard T., Sylla C., Benalia H., Fretz C., et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999, 29:257.
3. Degos F., Lugassy C., Degott C., Debure A., Carnot F., Theirs V., et al. Hepatitis B virus and hepatitis B-related viral infection in renal transplant recipients: a prospective study of 90 patients. Gastroenterology 1998, 94:151.
4. Marcellin P., Giostra E., Martinot-Peignoux M., Loriot M.A., Jaegle M.L., Wolf P., et al. Redevelopment of hepatitis B surface antigent after renal transplantation. Gastroenterology 1991, 100:1432.
5. Fabrizi F., Dulai G., Dixit V., Bunnapradist S., Martin P. Lamivudine for the treatment of hepatitis B-related liver disease after renal transplantation: meta-analysis of clinical trials. Transplantation 2004, 77:859.
6. Liaw Y.F., Sung J.J., Chow W.C., Farrell G., Lee C.Z., Yuen H., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004, 351:1521.
7. Liaw Y.F., Chien R.N., Yeh C.T. No benefit to continue lamivudine therapy after emergence of YMDD mutations. Antivir Ther 2004, 9:257.
8. Peters M.G., Hann H., Martin P., Heathcote E.J., Buggisch P., Rubin R., et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004, 126:91.
9. Lampertico P., Vigano M., Manenti E., Iavarone M., Sablon E., Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007, 133:1445.
10. Rapti I., Dimou E., Mitsoula P., Hadziyannis S.J. Adding-on versus switching- to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007, 45:307.
11. Kamar N., Milioto O., Alric L., El Kahwaji L., Cointault O., Lavayssiere L., et al. Entecavir therapy for adefovir-resistant hepatitis B virus infection in kidney and liver allograft recipients. Transplantation 2008, 86:611.
12. Haziyannis S.J., Tassopoulos N.C., Heathcote E.J., Chang T.T., Kitis G., Rizzetto M., et al. Long-term therapy with adefovir dipivoxil for HBeAg-Negative chronic hepatitis B for up to 5 Years. Gastroenterology 2006, 131:1743.
13. Gwak G.Y., Huh D.H., Lee D.H., Choi M.S., Lee J.H., Koh K.C., et al. The incidence and clinical outcome of YMDD mutants in hepatitis B surface antigen-positive renal allograft recipients after prolonged lamivudine therapy. Transplant Proc 2007, 39:3121.
14. Yuen M.F., Sablon E., Hui C.K., Yuan H.J., Decraemer H., Lai C.L. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001, 34:785.
15. Ha N.B., Ha N.B., Garcia R.T., Trinh H.N., Vu A.A., Nguyen H.A., et al. Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology 2009, 50:727.
16. de Silva H.J., Dassanayake A.S., Manamperi A., de Silva A.P. Treatment of lamivudine-resistant hepatitis B infection in post-renal transplant patients with adefovir dipivoxil: preliminary results. Transplant Proc 2006, 38:3118.
17. Olyaei A.J., de Mattos A.M., Bennett W.M. Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies. Curr Opin Crit Care 2001, 7:384.